A critique in need of critique

Public Health Ethics

Volumn 3, Issue 2, 2010, Pages 178-185

  Peterson, Matt ^a   Hollis, Aidan ^b   Pogge, Thomas ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG RESEARCH; ECONOMIC ASPECT; FUNDING; HEALTH CARE POLICY; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; REVIEW;

EID: 77955015970     PISSN: 17549973     EISSN: 17549981     Source Type: Journal    
DOI: 10.1093/phe/php037     Document Type: Review

References (17)

1. Attaran, A. and Gillespie-White, L. (2001). Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa? Journal of the American Medical Association, 286, 1886-1892.
2. Chaudhuri, S.,Goldberg, P. and Jia, P. (2003). Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India. NBER Working Paper No.W10159, December.
3. Chien, C. (2007). HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare? PLoS One, 3, 1-6.
4. Consumer Project on Technology. (2001). Comment on the Attaran/Gillespie-White and PhRMA Surveys of Patents on ARVs in Africa, October 16, http: //www. cptech.org/ip/health/africa/dopatentsmatterinafrica. html.
5. Eaton, L. (2005). Global Fund Toughens Stance against Corruption. British Medical Journal, 331, 718.
6. Hollis, A. and Pogge, T. (2008). The Health Impact Fund: Making New Medicines Accessible for All. New Haven, CT: Incentives for Global Health.
7. IRIN. (2009). UGANDA: Justice Slowly Meted Out in Global Fund Corruption Trials. August 19, http: // www.alertnet.org/thenews/newsdesk/IRIN/f1d5834fd 923321f7fd6ed59f3c2380c.htm.
8. Ḿedecins Sans Frontìeres. (2001). Patents Do Matter in Africa According toNGOs. Joint Statement byOxfam, Treatment Access Campaign, Consumer Project on Technology, Ḿedecins Sans Frontìeres, and Health GAP. October 17. http: //www.msfaccess.org/mediaroom/ press-releases/press-release-detail/?tx ttnews [tt news]=184&cHash= 4f545bfed4.
9. Ḿedecins Sans Frontìeres. (2008). Untangling the Web of Antiretroviral Price Reductions, 2008, 11th edn. Geneva: Ḿedecins Sans Frontìeres.
10. Pogge, T. (2005). Human Rights and Global Health: A Research Program. Metaphilosophy, 36, 182-209.
11. Saul, S. (2008). In Sour Economy, Some Scale Back on Medications. New York Times, October 21: A1.
12. Shadlen, K. (2007).The Political Economy ofAIDSTreatment: Intellectual Property and the Transformation of Generic Supply. International Studies Quarterly, 51, 559-581.
13. Sonderholm, J. (2009a). In Defence of Priority-Review Vouchers. Bioethics, 23, 413-420.
14. Sonderholm, J. (2009b). Paying a High Price for Low Costs: Why There Should Be No Legal Constraints on the Profits That Can Be Made on Drugs for Tropical Diseases. Journal of Medical Ethics, 35, 309-313.
15. Sonderholm, J. (2009c). A Reform Proposal in Need of Reform: A Critique of Thomas Pogge's Proposal for How to Incentivize Research and Development of Essential Drugs. Public Health Ethics, Advance Access published on July 3, 2009, doi: 10.1093/phe/php017.
16. Sonderholm, J. (2009d).Wild-Card Patent Extensions as a Means to Incentivize Research and Development of Antibiotics. Journal of Law, Medicine and Ethics, 37, 240-246.
17. Syed, T. (2009). Should a Prize System for Pharmaceuticals Require Patent Protection for Eligibility? Incentives for Global Health Discussion Paper #2.